TB Logo (wood) 

ANNOUNCEMENTS

September 9, 2013: DOH Medical Advisory – Update on Nationwide Shortage of Purified Protein Derivative (PPD) Solution Continues to Affect Hawaii (click to open and read advisory)
The nationwide shortage of Tubersol and limited availability of Aplisol have recurred.  Medical providers and institutions with a limited amount of PPD solution are encouraged to preserve supplies for persons with signs/symptoms suggestive of active TB as well as others at highest risk for developing active TB.  TB clearance requirements in the state remain in effect and the DOH TB clinics currently have adequate supplies of PPD.  Medical providers and institutions may refer clients who need a TB skin test to comply with state TB clearance requirements to a DOH TB clinic for this service.

July 9, 2013: DOH Medical Advisory – Department of Health to Restart TB Skin Testing in Clinics Statewide (click to open and read advisory)
The Hawaii State Department of Health (DOH) now has an adequate supply of solution used for TB skin testing and will resume providing the tuberculin skin test (TST) in all DOH tuberculosis (TB) clinics statewide on July 15, 2013. Availability of TB test solution appears to be returning to normal throughout Hawaii and the DOH encourages medical providers, clinics, and health care settings to resume providing the TST to their clients if they have supplies. People needing the test are encouraged to check with their provider.  A national shortage of PPD prompted the state to issue a 120-day suspension of TB clearance requirements that mandated in Hawaii Administrative Rules, Title 11, Chapter 164, for school personnel, students, food handlers, and workers in health care, domiciliary care, daycare, and residential care facilities. The temporary suspension of requirements for TB clearances expires on August 9, 2013. Students enrolling in post-secondary school for the first-time in Hawaii may receive additional guidance directly from their university or college.

February 6, 2013: DOH Guidance to Providers in Response to Critical National Isoniazid (INH) Shortage (click to open and read guidance)
This memo serves to guide all medical providers who are treating latent or active tuberculosis in the State of Hawaii, including providers at all state, federal, and private clinics who depend upon the Hawaii TB Control Program for medications.  Providers, if you need isoniazid (INH) for a high-risk patient, please call (808) 832-3539.

February 5, 2013: DOH Medical Advisory – Isoniazid (INH) Shortage (click to open and read advisory)
There is a nationwide shortage of isoniazid (INH), as reported in the December 21, 2012, Morbidity and Mortality Weekly Report.  INH is a potent and highly effective drug for treatment of latent tuberculosis infection (LTBI) and TB disease. This alert describes what is known about the INH shortage, provides steps to follow if your supply is limited, describes LTBI treatment options, and includes resources for questions or updates.  Providers, if you need isoniazid (INH) for a high-risk patient, please call (808) 832-3539.

 


 

Our Mission

To reduce the incidence of tuberculosis in the state by providing effective prevention, detection, treatment, and educational services.

 

Program Services and Activities

  • Offer diagnosis and treatment of TB.
  • Ensure that all cases and suspected cases of TB are identified and that appropriate therapy is provided.
  • Provide preventive therapy for patients at high risk of developing TB disease including contacts of active cases, persons who are HIV positive, and those with evidence of untreated TB.
  • Conduct direct TB services including chest X-ray, sputum smear and culture for mycobacteria, tuberculin skin testing, treatment with anti-tuberculosis therapy, and directly observed therapy (DOT) through TB clinics on the four most heavily populated islands.

 

This page last updated: September 16, 2013